1
|
Becker M, Somesh D, Klose K, Herrera A, Klein O, Jürchott K, Gossen M, Falk V, Stamm C. Human Cardiac ECM Hydrogel Coated Biological Scaffold upon Infarction Tailored for Epicardial Regeneration upon Infarction by Colonization of Transdifferentiated Cardiac Progenitors. Thorac Cardiovasc Surg 2019. [DOI: 10.1055/s-0039-1678983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- M. Becker
- Berlin Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany
| | - D. Somesh
- Berlin Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany
| | - K. Klose
- Charite - Universitaetsmedizin Berlin, Berlin, Germany
| | - A. Herrera
- Charité - Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies (BCRT), Berlin, Germany
| | - O. Klein
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
| | - K. Jürchott
- Charite - Universitaetsmedizin Berlin, Berlin, Germany
| | - M. Gossen
- Institute of Biomaterial Science, Helmholtz-Zentrum Geesthacht, Teltow, Berlin, Germany
| | - V. Falk
- Deutsches Herzzentrum Berlin, Berlin, Germany
| | - C. Stamm
- Deutsches Herzzentrum Berlin, Berlin, Germany
| |
Collapse
|
2
|
Pivovarova O, Kessler K, Jürchott K, Hornemann S, Sticht C, Kemper M, Gretz N, Rudovich N, Kramer A, Pfeiffer AFH. Effects of the diurnal distribution of carbohydrates and fat on the adipose tissue transcriptome in humans. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- O Pivovarova
- German Institute of Human Nutrition Potsdam-Rehbruecke, Dept. of Clinical Nutrition, Nuthetal, Germany
- Charité University Medicine, Dept. of Endocrinology, Diabetes and Nutrition, Campus Benjamin Franklin, Berlin, Germany
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - K Kessler
- German Institute of Human Nutrition Potsdam-Rehbruecke, Dept. of Clinical Nutrition, Nuthetal, Germany
- Charité University Medicine, Dept. of Endocrinology, Diabetes and Nutrition, Campus Benjamin Franklin, Berlin, Germany
| | - K Jürchott
- Charité University Medicine, Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Berlin, Germany
| | - S Hornemann
- German Institute of Human Nutrition Potsdam-Rehbruecke, Dept. of Clinical Nutrition, Nuthetal, Germany
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - C Sticht
- Faculty of Medicine Mannheim at Heidelberg University, Center for medical research (ZMF), Mannheim, Germany
| | - M Kemper
- German Institute of Human Nutrition Potsdam-Rehbruecke, Dept. of Clinical Nutrition, Nuthetal, Germany
- Charité University Medicine, Dept. of Endocrinology, Diabetes and Nutrition, Campus Benjamin Franklin, Berlin, Germany
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - N Gretz
- Faculty of Medicine Mannheim at Heidelberg University, Center for Medical Research (ZMF), Mannheim, Germany
| | - N Rudovich
- German Institute of Human Nutrition Potsdam-Rehbruecke, Dept. of Clinical Nutrition, Nuthetal, Germany
- Charité University Medicine, Dept. of Endocrinology, Diabetes and Nutrition, Campus Benjamin Franklin, Berlin, Germany
- Spital Bülach, Division of Endocrinology and Diabetes, Department of Internal Medicine, Bülach, Switzerland
| | - A Kramer
- Charité University Medicine, Laboratory of Chronobiology, Institute for Medical Immunology, Berlin, Germany
| | - AFH Pfeiffer
- German Institute of Human Nutrition Potsdam-Rehbruecke, Dept. of Clinical Nutrition, Nuthetal, Germany
- Charité University Medicine, Dept. of Endocrinology, Diabetes and Nutrition, Campus Benjamin Franklin, Berlin, Germany
- German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| |
Collapse
|
3
|
Reidell O, Somesh D, Klose K, Protze S, Kunkel D, Krüger U, Jürchott K, Falk V, Gossen M, Stamm C. Maturation of Induced Cardiomyocyte Precursor Cells Created by Direct Reprogramming. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1627947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- O. Reidell
- Charite - Universitaetsmedizin Berlin, BCRT, Berlin, Germany
| | - D. Somesh
- Charite - Universitaetsmedizin Berlin, BCRT, Berlin, Germany
| | - K. Klose
- Charite - Universitaetsmedizin Berlin, BCRT, Berlin, Germany
| | - S. Protze
- Charite - Universitaetsmedizin Berlin, BCRT, Berlin, Germany
| | - D. Kunkel
- Charite - Universitaetsmedizin Berlin, BCRT, Berlin, Germany
| | - U. Krüger
- Charite - Universitaetsmedizin Berlin, BCRT, Berlin, Germany
| | - K. Jürchott
- Charite - Universitaetsmedizin Berlin, BCRT, Berlin, Germany
| | - V. Falk
- Deutsches Herzzentrum Berlin, Berlin, Germany
| | - M. Gossen
- Charite - Universitaetsmedizin Berlin, BCRT, Berlin, Germany
| | - C. Stamm
- Deutsches Herzzentrum Berlin, Berlin, Germany
| |
Collapse
|
4
|
Somesh D, Klose K, Protze S, Kunkel D, Krüger U, Jürchott K, Gossen M, Falk V, Stamm C. Next Generation Sequencing Reveals a Committed but Immature Phenotype of Induced Cardiomyocyte Progenitor Cells. Thorac Cardiovasc Surg 2017. [DOI: 10.1055/s-0037-1598858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- D.B. Somesh
- Charité Universitätsmedizin Berlin, Berlin Center for Regenerative Medicine, Berlin, Germany
| | - K. Klose
- Charité Universitätsmedizin Berlin, Berlin Center for Regenerative Medicine, Berlin, Germany
| | - S. Protze
- McEwen Centre for Regenerative Medicine, Toronto, Canada,
| | - D. Kunkel
- Charité Universitätsmedizin Berlin, Berlin Center for Regenerative Medicine, Berlin, Germany
| | - U. Krüger
- Charité Universitätsmedizin Berlin, Berlin Center for Regenerative Medicine, Berlin, Germany
| | - K. Jürchott
- Charité Universitätsmedizin Berlin, Berlin Center for Regenerative Medicine, Berlin, Germany
| | - M. Gossen
- Charité Universitätsmedizin Berlin, Berlin Center for Regenerative Medicine, Berlin, Germany
| | - V. Falk
- Deutsches Herzzentrum Berlin, Herz-, Thorax- und Gefäßchirurgie, Berlin, Germany
| | - C. Stamm
- Deutsches Herzzentrum Berlin, Herz-, Thorax- und Gefäßchirurgie, Berlin, Germany
| |
Collapse
|
5
|
Pivovarova O, Jürchott K, Rudovich N, Hornemann S, Lu Y, Möckel S, Murahovschi V, Kessler K, Seltmann AC, Maser-Gluth C, Mazuch J, Kruse M, Busjahn A, Kramer A, Pfeiffer AFH. Changes of dietary fat and carbohydrate content alter central and peripheral clock in humans. Exp Clin Endocrinol Diabetes 2015. [DOI: 10.1055/s-0035-1547612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Pivovarova O, Hornemann S, Lu Y, Möckel S, Murahovschi V, Kessler K, Seltmann AC, Maser-Gluth C, Mazuch J, Rudovich N, Kruse M, Jürchott K, Busjahn A, Kramer A, Pfeiffer AFH. An isocaloric high fat diet affects peripheral circadian clock and diurnal rhythms of inflammatory genes in humans. Exp Clin Endocrinol Diabetes 2014. [DOI: 10.1055/s-0034-1372313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Hornemann S, Maser-Gluth C, Jürchott K, Pivovarova O, Kramer A, Busjahn A, Pfeiffer AF. The influence of different nutrition interventions on the circadian pattern of the glucocorticoid metabolism by twins. Exp Clin Endocrinol Diabetes 2014. [DOI: 10.1055/s-0034-1372152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Abdul-Ghani R, Serra V, Györffy B, Jürchott K, Solf A, Dietel M, Schäfer R. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 2006; 25:1743-52. [PMID: 16288223 DOI: 10.1038/sj.onc.1209201] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Multidrug resistance may be achieved by the activation of membrane transporters, detoxification, alterations in DNA repair or failure in apoptotic pathways. Recent data have suggested an involvement of mitogenic signalling pathways mediated by Ras and phosphoinositol-3-kinase (PI3K/Akt) in controlling multidrug resistance. Since these pathways are important targets for therapeutic interference, we sought to investigate whether blocking effectors kinases by specific inhibitors would result in a sensitization toward cytotoxic drugs. We found that cotreatment of drug-resistant HT29RDB colon cancer cells with the topoisomerase inhibitor doxorubicin and the PI3K-inhibitor LY294002 resulted in massive apoptosis, while cotreatment with the Mek inhibitors PD98059 or U0126 had no effect. This suggested that the PI3K-pathways controls cell survival and drug resistance in these cells. Besides blocking Akt phosphorylation, the PI3K-inibitor increased the intracellular doxorubicin concentration threefold. LY294002 inhibits drug export in a competitive manner as revealed by measuring drug efflux in the presence and the absence of inhibitor. The efficacy of drug efflux inhibition by LY294002 was similar to that achieved by the MRP1 inhibitors MK571 and genistein. We conclude that the PI3K inhibitor LY294002 may have therapeutic potential when combined with doxorubicin in the treatment of MRP1-mediated drug resistance.
Collapse
Affiliation(s)
- R Abdul-Ghani
- Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité, Universitätsmedizin Berlin, Schumannstr, D-10117 Berlin, Germany
| | | | | | | | | | | | | |
Collapse
|
9
|
Gessner C, Woischwill C, Schumacher A, Liebers U, Kuhn H, Stiehl P, Jürchott K, Royer HD, Witt C, Wolff G. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir J 2004; 23:14-9. [PMID: 14738225 DOI: 10.1183/09031936.03.00033203] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The human Y-box binding protein, YB-1, is a multifunctional protein that regulates gene expression. Nuclear expression of YB-1 has been associated with chemoresistance and poor prognosis of tumour patients. Representative samples from autopsied material of primary tumours from 77 patients with NSCLC were investigated by immunohistochemistry for subcellular distribution of YB-1 and p53, in order to evaluate the prognostic role of nuclear expression of YB-1. Cytoplasmic YB-1 expression was found in all tumour samples, whereas nuclear expression was only observed in 48%. There was no correlation with histological classification, clinical parameters or tumour size, stage and metastasis status. However, patients with positive nuclear YB-1 expression in tumours showed reduced survival times when compared with patients without nuclear expression. Including information about the histology and mutational status for p53 increased the prognostic value of nuclear YB-1. Patients with nuclear YB-1 expression and p53 mutations had the worst prognosis (median survival 3 months), while best outcome was found in patients with no nuclear YB-1 and wildtype p53 (median survival 15 months). This suggests that the combined analysis of both markers allows a better identification of subgroups with varying prognosis. Nuclear expression of Y-box binding protien seems to be an independent prognostic marker.
Collapse
Affiliation(s)
- C Gessner
- Dept of Internal Medicine, Pneumology, University of Leipzig, Leipzig, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Stein U, Jürchott K, Walther W, Bergmann S, Schlag PM, Royer HD. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 2001; 276:28562-9. [PMID: 11369762 DOI: 10.1074/jbc.m100311200] [Citation(s) in RCA: 108] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Genotoxic stress leads to nuclear translocation of the Y-box transcription factor YB-1 and enhanced expression of the multidrug resistance gene MDR1. Because hyperthermia is used for the treatment of colon cancer in combination with chemoradiotherapy, we investigated the influence of hyperthermia on YB-1 activity and the expression of multidrug resistance-related genes. Here we report that hyperthermia causes YB-1 translocation from the cytoplasm into the nucleus of human colon carcinoma cells HCT15 and HCT116. Nuclear translocation of YB-1 was associated with increased MDR1 and MRP1 gene activity, which is reflected in strong efflux pump activity. However, a combination of hyperthermia and drug treatment effectively reduced cell survival of the HCT15 and HCT116 cells. These results demonstrate that activation of MDR1 and MRP1 gene expression and increased efflux pump activity after hyperthermia were insufficient to cause an increase in drug resistance in colon cancer cell lines. The ability of hyperthermia to abrogate drug resistance in the presence of an increase in functional MDR proteins may provide an explanation for the efficacious results seen in the clinic in colon cancer patients treated with a combination of hyperthermia and chemotherapy.
Collapse
Affiliation(s)
- U Stein
- Max-Delbrück Center for Molecular Medicine, Robert-Rössle Strasse 10, 13092 Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
11
|
Chen CY, Gherzi R, Andersen JS, Gaietta G, Jürchott K, Royer HD, Mann M, Karin M. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev 2000; 14:1236-48. [PMID: 10817758 PMCID: PMC316620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2000] [Accepted: 03/30/2000] [Indexed: 02/16/2023]
Abstract
Regulated mRNA turnover is a highly important process, but its mechanism is poorly understood. Using interleukin-2 (IL-2) mRNA as a model, we described a role for the JNK-signaling pathway in stabilization of IL-2 mRNA during T-cell activation, acting via a JNK response element (JRE) in the 5' untranslated region (UTR). We have now identified two major RNA-binding proteins, nucleolin and YB-1, that specifically bind to the JRE. Binding of both proteins is required for IL-2 mRNA stabilization induced by T-cell activation signals and for JNK-induced stabilization in a cell-free system that duplicates essential features of regulated mRNA decay. Nucleolin and YB-1 are required for formation of an IL-2 mRNP complex that responds to specific mRNA stabilizing signals.
Collapse
Affiliation(s)
- C Y Chen
- Department of Pharmacology, University of California San Diego, La Jolla, California 92093, USA
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B, Royer HD. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3:447-50. [PMID: 9095180 DOI: 10.1038/nm0497-447] [Citation(s) in RCA: 330] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Breast cancers are either primarily resistant to chemotherapy (intrinsic resistance), or respond to chemotherapy but later recur with a multidrug-resistant phenotype because of overexpression of the multidrug transporter P-glycoprotein. The MDR1 gene encoding P-glycoprotein may be transcriptionally regulated by a Y-box transcription factor. We now report that, in multidrug-resistant MCF-7 breast cancer cells, nuclear localization of YB-1 is associated with MDR-1 gene expression. In drug-sensitive MCF-7 cells, however, YB-1 was localized to the cytoplasm. Regulated overexpression of YB-1 in drug-sensitive diploid breast epithelial cells induced MDR-1 gene expression and multidrug resistance. In 27 out of 27 untreated primary breast cancers, YB-1 protein was expressed in the cytoplasm although it was undetectable in normal breast tissue of these patients. In a subgroup of tumors (9/27), however, YB-1 was also localized to the nucleus and, in these cases, high levels of P-glycoprotein were present. These results show that in a subset of untreated primary breast cancers, nuclear localization of YB-1 protein is associated with intrinsic multidrug resistance. Our data show that YB-1 has an important role in controlling MDR1 gene transcription and this finding provides a basis for the analysis of molecular mechanisms responsible for intrinsic multidrug resistance in human breast cancer.
Collapse
Affiliation(s)
- R C Bargou
- Humboldt Universität zu Berlin, Universitätsklinikum Rudolf Virchow, Robert-Rössle Klinik, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|